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NOACs are All Associated With a Significant 
Standardized Absolute Risk Reduction of MI 
Compared With VKA   
Among 31,739 patients with atrial fibrillation 
(AF) (median age, 74 years; 47% females), the 
standardized 1-year risk of MI for VKA was 1.6%, 
1.2% for apixaban, 1.2% for dabigatran, and 1.1% for 
rivaroxaban. No significant risk differences were 
observed in the standardized 1-year risks of MI 
among the NOACs: dabigatran vs apixaban (0.04%), 
rivaroxaban versus apixaban (0.1%), and rivaroxaban 
versus dabigatran (−0.1%). The risk differences for 
NOACs vs VKA were all significant: −0.4% for 
apixaban, −0.4% for dabigatran, and −0.5% for 
rivaroxaban (Lee CJ-Y et al, J Am Coll Cardiol 2018;72: 
17–26).   
ATLAS ACS 2-TIMI 51 Trial: In Patients With ACS, 
Addition of Rivaroxaban, 2.5 mg bid, to Dual 
Antiplatelet Therapy With Aspirin and Clopidogrel 
Was Associated With a Net Reduction in Fatal or 
Irreversible Events Compared to Dual Antiplatelet 
Therapy Alone  
Rivaroxaban, 2.5 mg bid, in ACS patients treated with 
aspirin and clopidogrel/ticlopidine was associated with 
115 fewer fatal or irreversible ischemic events (663 for 
placebo vs 548 for therapy) and 10 additional fatal or 
irreversible seriously harmful events (33 vs 23 for placebo) 
per 10,000 patient-years of exposure. Thus, there would be 
105 fatal or irreversible events prevented per 10,000 
patient-years of exposure to rivaroxaban compared with 
placebo, with 11 (10 of 115) fatal or irreversible ischemic 
events prevented for each fatal or irreversible seriously 
harmful event caused. If only nonbleeding cardiovascular 
death is included as a fatal or irreversible event, then 95 
events would be prevented per 10,000 patient-years of 
exposure in the group taking 2.5 mg bid (Gibson CM et al, 
J Am Coll Cardiol 2018;72: 129-36).   
XANTUS Program: In a Pooled Analysis of Several 
Practice-Based Registries, AF Patients on Rivaroxaban 
Had Generally Low Rates of Stroke, Bleeding, and 
Treatment Discontinuation and Results Were Broadly 
Consistent Across Different Regions of the World   
Among 11,121 AF patients receiving rivaroxaban 
(mean age 70.5±10.5 years; female 42.9%) with 
comorbidities including heart failure (21.2%), 
hypertension (76.2%), and diabetes (22.3%), event rates 
were: events/100 patient-years: major bleeding 1.7 
(lowest: Latin America 0.7; highest: Western Europe, 
Canada, and Israel 2.3); all-cause death 1.9 (lowest: 
Eastern Europe 1.5; highest: Latin America, Middle East, 
and Africa 2.7); and stroke or systemic embolism 1.0 
(lowest: Latin America 0; highest: East Asia 1.8). One-
year treatment persistence was 77.4% (lowest: East Asia 
66.4%; highest: Eastern Europe 84.4%) (Kirchhof P et al, 
J Am Coll Cardiol 2018;72:141-53).  
In Patients With AMI Complicated by Cardiogenic 
Shock (CS) Who Have Undergone Successful Primary 
Angioplasty, Shock is Less Refractory When Arterial 
Pressure is Supported With Norepinephrine Rather 
Than With Epinephrine   
Patients (N=57) with CS were randomized into 2 study 
arms, epinephrine (n=27) and norepinephrine (n=30). For 
the primary efficacy endpoint, cardiac index evolution was 
similar between the 2 groups from baseline (H0) to H72. 
For the main safety endpoint, the observed higher 
incidence of refractory shock in the epinephrine group 
(37% vs norepinephrine 7%; p=0.008) led to early 
termination of the study. Heart rate increased significantly 
with epinephrine from H2 to H24 while it remained 
unchanged with norepinephrine (p<0.0001). Several 
metabolic changes were unfavorable to epinephrine 
compared with norepinephrine, including an increase in 
cardiac double product (p=0.0002) and lactic acidosis from 
H2 to H24 (p< 0.0001) (Levy B et al, J Am Coll Cardiol 
2018; 72:173-82)  
Valve-in-Valve (ViV)-TAVI Can be a Safe and 
Effective Alternative to Cardiac Reoperation for High-
Risk Patients With Degenerated Bioprosthetic Aortic 
Valves   
Patients who underwent ViV-TAVI (n=1,150) were 
matched 1:2 to patients undergoing native valve (NV)-
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TAVI (n=2,259). A lower 30-day mortality (2.9% vs 4.8%; 
p< 0.001), stroke (1.7% vs 3.0%; p=0.003), and heart 
failure hospitalizations (2.4% vs 4.6%; p<0.001) were 
observed in the ViV-TAVI compared with NV-TAVI 
group. A lower 30-day mortality (hazard ratio-HR: 0.503; 
p=0.008), 1-year mortality (HR: 0.653; p=0.001), and 
hospitalization for heart failure (HR: 0.685; p=0.019) were 
noted in the ViV-TAVI group. Patients in the ViV-TAVI 
group had higher post-TAVI mean gradient (16 vs 9 
mmHg; p< 0.001), but less moderate or severe aortic 
regurgitation (3.5% vs 6.6%; p<0.001). Post-TAVI 
gradients were highest in small AVRs and stenotic AVRs 
(Tuzcu EM et al, J Am Coll Cardiol 2018; 72:370-82).   
NODE-1: Intra-Nasal Etripamil, a Short-Acting 
Calcium Channel Blocker, with a Rapid Onset of 
Action, was More Effective Than Placebo in 
Terminating Induced SVT, Though a High Dose was 
Associated With Lowering of Blood Pressure  
Among 104 patients with induced SVT, conversion 
rates were between 65% and 95% in the etripamil nasal 
spray groups and 35% in the placebo group; differences 
were significant in the 3 highest active compound dose 
groups versus placebo. In patients who converted, the 
median time to conversion with etripamil was <3 min. 
Adverse events were mostly related to the intranasal route 
of administration or local irritation. Reductions in blood 
pressure occurred predominantly in the highest etripamil 
dose (Stambler BS et al, J Am Coll Cardiol 2018; 72:489-
97).   
Contemporary Medical Treatment of Heart Failure 
(HF) With Depressed Ejection Fraction is Associated 
With an Early Rise in LVEF, Followed by a Plateau for 
About a Decade and a Slow Decline Thereafter  
Measurements (3.6±1.7) of left ventricular ejection 
fraction (LVEF) trajectories among 1,160 HF patients 
projected by Loess spline curves showed an inverted U 
shape with a marked rise in LVEF during the first year, 
maintained up to a decade, and a slow LVEF decline 
thereafter (p <0.001). This pattern was more pronounced 
in HF of nonischemic origin and in women. Patients with 
new-onset HF (≤1 year) had a higher early increase in 
LVEF, whereas patients with ischemic HF showed a lower 
LVEF increase at 1 year; both groups had a relative plateau 
thereafter. Patients with HF with mid-range LVEF had less 
of an increase (3±9%) than those with HF with reduced 
LVEF (9±12%) during the first year (p< 0.001), but the 
groups overlapped after 15 years. Patients who died had 
lower final LVEF and worse LVEF dynamics in the 
immediately preceding period than survivors (Lupon J et 
al, J Am Coll Cardiol 2018;72:591-601).   
APACE & BACC Studies: The European Society of 
Cardiology 0/1-h Algorithm Based on High-Sensitivity 
Cardiac Troponin T 0r I, Used in Conjunction With All 
Other Clinical Information Including Chest Pain 
Characteristics and the ECG, is Safe and Effective in 
Triaging Patients With Suspected NSTEMI   
Prevalence of NSTEMI among patients presenting to 
the emergency room was 17%. Among 4,368 patients with 
serial hs-cTnT measurements available, safety of rule-out 
(negative predictive value-NPV 99.8%), accuracy of rule-
in (positive predictive value-PPV 74.5%), and overall 
efficacy were high by assigning 3/4 of patients either to 
rule-out (57%) or rule-in (18%). Similarly, among 3,500 
patients with serial hs-cTnI measurements, safety of rule-
out (NPV 99.7%), accuracy of rule-in (PPV 62.3%), and 
overall efficacy were high by assigning >2/3 of patients 
either to rule-out (44%) or rule-in (23%). Excellent safety 
was confirmed in multiple subgroup analyses including 
patients presenting early (≤3 h) after chest pain onset. 
(Twerenbold R et al, J Am Coll Cardiol 2018;72:620-32).   
RAID Trial: In High-Risk Patients With Heart Failure 
and Implanted Defibrillators (ICDs), Ranolazine 
Failed to Reduce the Primary Endpoint of VT, VF, or 
Death; in Secondary Analyses, Ranolazine Reduced 
Recurrent VT or VF Requiring ICD Therapy, Mainly 
Through Reduction in Episodes of VT Without 
Increasing Proarrhythmia or Associated Mortality  
Among 1,012 ICD patients (510 on ranolazine and 502 
on placebo; aged 64±10 years; 18% women), over 28±16 
months, there were 372 (37%) patients with primary 
endpoint, 270 (27%) patients with VT or VF, and 148 
(15%) deaths. The study drug was stopped in 199 (39.6%) 
patients receiving placebo and in 253 (49.6%) receiving 
ranolazine (p=0.001). The hazard ratio-HR for ranolazine 
vs placebo was 0.84 (p=0.117) for VT, VF, or death. In a 
pre-specified secondary analysis, patients randomized to 
ranolazine had a marginally significant lower risk of ICD 
therapies for recurrent VT or VF (HR: 0.70; p=0.028) 
(Zareba W et al, J Am Coll Cardiol 2018;72: 636-45).   
In Low-/Intermediate-Risk Patients With 
Hypertrophic Cardiomyopathy (HCM) (Obstructive, 
Myectomy, Nonobstructive Groups) With Preserved 
Systolic Function, %LGE was Associated With a 
Higher Rate of Composite Endpoint (Sudden Death/ 
Appropriate ICD Discharge) 
Among 1,423 low-/intermediate-risk patients with 
HCM (age ≥18 years) with preserved left ventricular 
ejection fraction (mean age 66 ± 14 years, 60% men), mean 
5-year SCD risk score of 2.3±2.0, 50% had late gadolinium 
enhancement (LGE) on CMR (458 nonobstructive and 965 
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obstructive of whom 686 had myectomy). At 4.7±2.0 
years, 60 (4%) met the composite endpoint (sudden 
death/appropriate ICD discharge). On quadratic spline 
analysis, LGE ≥15% was associated with increased risk of 
composite events. In the obstructive subgroup, ≥15% LGE 
(subhazard ratio: 3.04) was associated with a higher rate 
and myectomy (subhazard ratio: 0.44) with a lower rate of 
composite endpoints (both p< 0.01). Association of %LGE 
with composite events was similar in myectomy and 
nonobstructive subgroups (Mentias A et al, J Am Coll 
Cardiol 2018;72:857–70).   
Takotsubo Syndrome (TTS): Long-Term Outcome 
Highly Variable / Prognosis is More Favorable When 
the Syndrome is Triggered by Emotional Events Than 
When it Develops in Response to Physical or 
Neurologic Conditions   
Overall, TTS patients had a comparable long-term 
mortality risk with acute coronary syndrome (ACS) 
patients. Of 1,613 TTS patients, emotional trigger was 
detected in 485 patients (30%); of 630 patients (39%) 
related to physical triggers, 98 patients (6%) had acute 
neurologic disorders, while in the other 532 patients 
(33%), physical activities, medical conditions, or 
procedures were the triggering conditions. The remaining 
498 patients (31%) had no identifiable trigger. TTS 
patients related to physical stress showed higher mortality 
rates than ACS patients during long-term follow-up, 
whereas patients related to emotional stress had better 
outcomes compared with ACS patients (Ghadri JR et al J 
Am Coll Cardiol 2018;72:874–82).   
SUMMIT Trial: In Patients With COPD and High 
Cardiovascular (CV) Risk, Plasma Cardiac Troponin I 
(cTnI) Concentrations were an Indicator of Future CV 
Events and CV Death / Inhaled Therapies Did not 
Affect cTnI Levels Consistent With Their Neutral 
Effect on Mortality and CV Outcomes   
Among 16,485 COPD patients with CV disease or risk 
factors, randomized to once daily inhaled placebo, 
fluticasone furoate (100 μg), vilanterol (25 μg), or their 
combination, plasma high-sensitivity cTnI was measured 
in a subgroup of 1,599 patients. Baseline cTnI levels were 
above the limit of detection (1.2 ng/l) in 1,542 (96%) 
patients. Concentrations were unaffected by inhaled 
therapies at 3 months (p > 0.05). Compared with the lowest 
quintile (<2.3 ng/l), patients in the highest quintile (≥7.7 
ng/l) were at greater risk of CV events (hazard ratio-HR 
3.7; p=0.012) and CV death (HR: 20.1; p=0.005) after 
adjustment for risk factors. By contrast, there were no 
differences in exacerbations between quintiles (HR: 1.1; 
p=0.548) (Adamson PD et al, J Am Coll Cardiol 
2018;72:1126-37).   
Chronic Coronary Artery Disease (CAD): Low 
Diastolic Blood Pressure (DBP) May Precipitate or 
Worsen Angina / Should Consider Reducing 
Antihypertensive Medications in Patients With CAD 
and Low DBP Who Have Angina  
Among 1,259 outpatients with CAD, 411 (33%) 
reported angina in the prior month, with higher rates in the 
lowest DBP quartile (40-64 mmHg: 37%). In the 
unadjusted model, DBP was associated with angina with a 
J-shaped relationship (p=0.017, p for nonlinearity=0.027), 
with a progressive increase in odds of angina as DBP 
decreased below ∼70-80 mmHg. This association 
remained significant after sequential adjustment for 
demographic characteristics (p=0.002), comorbidities 
(p=0.002), heart rate (p=0.002), systolic BP (p=0.046), and 
antihypertensive antianginal medications (p=0.045) (Peri-
Okonny PA et al, J Am Coll Cardiol 2018;72:1227-32).  
Atrial Fibrillation (AF) Patients Treated for 
Hypertension: There is a U-Shaped Relationship 
Between BP and CV Events, With Optimum Outcomes 
Associated With a BP Range of 120-129/<80 mmHg  
Among 298,374 Korean adults with AF, 62.2% had 
hypertension (HTN) according with the old guidelines; 
applying the 2017 ACC/AHA guideline, 79.4% had HTN, 
including 17.2% with newly redefined HTN (130-139/80-
89 mmHg). Those with newly redefined hypertension had 
greater risks of major CV events (hazard ratio: 1.07; p< 
0.001), ischemic stroke, intracranial hemorrhage, and heart 
failure admission, compared with non-hypertensive 
patients (<130/80 mmHg). Among patients with AF 
receiving HTN treatment, patients with BP≥130/80 mmHg 
or <120/80 mmHg were at significantly higher risks of 
major CV events than patients with BP of 120-129/<80 
mmHg (Kim D et al, J Am Coll Cardiol 2018;72:1233–45).   
LIMA-Radial Artery (RA)-Y Graft Technique is 
Superior Compared to LIMA+SVG in Achieving Total 
Arterial Revascularization (TAR)  
Survival was compared between 346 LIMA-RA-Y 
patients and 534 patients who received LIMA+ SVG, and 
5,800 patients who received TAR with different grafting 
configurations. Survival was worse for LIMA+SVG vs 
LIMA-RA-Y (27.9% vs 53.5 still alive at 15 years) in the 
unmatched groups (KM, p< 0.001) and for propensity 
score matching (PSM) groups (KM, p=0.043; Cox 
proportional hazards ratio: 1.3; p=0.038). Survival did not 
differ between LIMA-RA-Y and other TAR (n=5,800) 
patients before, or after, PSM (n=332 pairs) (Royse AG et 
al, J Am Coll Cardiol 2018;72:1332–40).  
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Fluoroquinolones are Associated With a 2.5-Fold 
Increased Risk of Aortic Aneurysm and Dissection 
(AA/AD) 
Among 1,213 hospitalized AA/AD patients, exposure 
to fluoroquinolone was more frequent during the hazard 
periods than during the referent periods (1.6% vs 0.6%; 
odds ratio-OR: 2.71). In the sensitivity analysis, after 
adjustment for infections and co-medications, the risk 
remains significant (OR: 2.05). An increased risk of 
AA/AD was observed for prolonged exposure to 
fluoroquinolones (OR: 2.41 for 3- to 14-day exposure; OR: 
2.83 for >14-day exposure). Susceptible period analysis 
revealed that the use of fluoroquinolone within 60 days 
was associated with the highest risk of AA/AD. In the 
case-time-control analysis, there was no evidence that the 
observed association is due to temporal changes in 
fluoroquinolone exposure (Lee C-C et al, J Am Coll 
Cardiol 2018;72:1369–78).  
 
Very Elderly (≥90 Years) AF Patients: Warfarin was 
Associated With a Lower Risk of Ischemic Stroke and 
Positive Net Clinical Benefit / Compared With 
Warfarin, NOACs were Associated With a Lower Risk 
of Intracranial Hemorrhage (ICH)  
In the era without NOACs, risks of ischemic stroke 
and ICH were compared between 14,658 very elderly 
patients without AF and without antithrombotic therapy 
and 15,756 AF patients who were divided into 3 groups: 
no treatment (n=11,064), antiplatelet agents (n=4,075), 
and warfarin (n=617). In the era with NOACs, AF patients 
receiving warfarin (n=768) were compared with those 
receiving NOACs (n=978). Compared with patients 
without AF, AF patients had an increased risk of ischemic 
stroke (hazard ratio-HR, 1.93) and similar risk of ICH (HR, 
0.85). Among patients with AF, warfarin use was 
associated with a lower stroke risk (HR, 0.69), with no 
difference in ICH risk compared with nontreatment. When 
compared with no antithrombotic therapy or antiplatelet 
drugs, warfarin was associated with a positive net clinical 
benefit. These findings persisted in propensity-matched 
analyses. Compared with warfarin, NOACs were 
associated with a lower risk of ICH (4/978, 0.42%/y vs 
19/768, 1.63%/y; HR, 0.32), with no difference in risk of 
ischemic stroke (Chao T-F et al, Circulation 2018;138:37-
47.  
H2FPEF Score Enables Discrimination of HFpEF from 
Noncardiac Causes of Dyspnea 
A new score (H2FPEF: Heavy, BMI>30 kg/m2, 2 
points; Hypertensive, >2 drugs, 1 point; atrial Fibrillation, 
3 points; Pulmonary hypertension, >35 mmHg by Doppler, 
1 point; Elder, >60 years, 1 point; Filling pressure, E/e΄>9, 
1 point) (0-9 points) was derived from 414 consecutive 
patients (derivation cohort) with unexplained dyspnea 
(267 cases with HFpEF and 147 controls; HFpEF 
prevalence, 64%) and tested in 100 patients (test cohort) 
(61 with HFpEF; prevalence, 61%). The odds of HFpEF 
doubled for each 1-unit score increase (odds ratio, 1.98; 
P<0.0001), with an area under the curve of 0.841 
(P<0.0001). The H2FPEF score was superior to a currently 
used algorithm based on expert consensus (increase in area 
under the curve of 0.169; P<0.0001). Performance in the 
independent test cohort was maintained (area under the 
curve, 0.886; P<0.0001) (Reddy YNV et al, Circulation 
2018;138:861–870).   
CANVAS Program: In High Cardiovascular (CV) Risk 
Patients With Type 2 Diabetes (T2DM), Canagliflozin 
Reduced Risk of CV Death or Hospitalized HF / 
Benefits May Be Greater in Those With a History of 
Heart Failure (HF) at Baseline  
Among 10,142 participants with T2DM and high CV 
risk, randomly assigned to canagliflozin or placebo and 
followed for a mean of 3.6 years, the primary end point 
(CV death or hospitalized HF) was reduced in those treated 
with canagliflozin (16.3 vs 20.8 per 1000 patient-years; 
hazard ratio - HR, 0.78), as was fatal or hospitalized HF 
(HR, 0.70) and hospitalized HF alone (HR, 0.67). The 
benefit on CV death or hospitalized HF may be greater in 
patients with a prior history of HF (HR, 0.61) constituting 
14.4% of the whole group. The effects of canagliflozin 
compared with placebo on other CV outcomes and key 
safety outcomes were similar in participants with and 
without HF at baseline, except for a possibly reduced 
absolute rate of events attributable to osmotic diuresis 
among those with a prior history of HF (P=0.03) (Radholm 
K et al, Circulation 2018;138:458–468).   
After Left Atrial Appendage (LAA) Closure With 
Watchman, Device-Related Thrombus (DRT) was 
Observed in ≈3.7% and was Associated With a Higher 
Rate of Stroke and Systemic Embolism 
Of 1739 patients in 4 studies (PROTECT-AF / 
PREVAIL / CAP / CAP2) who received an implant (7159 
patient-years follow-up; CHA2DS2-VASc=4.0), DRT was 
seen in 65 patients (3.74%). The rates of stroke or systemic 
embolism (SSE) with and without DRT were 7.46 and 1.78 
per 100 patient-years (rate ratio - RR, 3.55; P<0.001), and 
ischemic SSE rates were 6.28 and 1.65 per 100 patient-
years (RR, 3.22, P<0.001). Predictors of DRT were: 
history of TIA or stroke (odds ratio - OR, 2.31; P=0.007), 
permanent AF (OR, 2.24; P=0.012); vascular disease (OR, 
2.06; P=0.028); LAA diameter (OR, 1.06 per mm increase; 
P=0.019); left ventricular ejection fraction (OR, 0.96 per 
1% increase; P=0.009). DRT and SSE both occurred in 17 
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of 65 patients (26.2%). Of the 19 SSE events in these 
patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) 
occurred within 1 and 6 months of DRT detection. After 
LAA closure, most SSEs (123/142, 86.62%) occurred in 
patients without DRT (Dukkipati SR et al, Circulation 
2018;138:874–85).  
Acute Myocarditis (AM): In a Contemporary Study, 
Overall Serious Adverse Events After AM Were Lower 
Than Previously Reported / Patients With Left 
Ventricular Ejection Fraction (LVEF) <50%, 
Ventricular Arrhythmias, or Low Cardiac Output 
Syndrome at Presentation Were at Higher Risk  
Among 443 patients (median age, 34 years; 19.4% 
female) with AM diagnosed by either endomyocardial 
biopsy (12.6%) and/or increased troponin plus edema and 
late gadolinium enhancement at cardiac magnetic 
resonance (CMR) (93.7%), at presentation, 118 patients 
(26.6%) had LVEF <50%, sustained ventricular 
arrhythmias, or a low cardiac output syndrome. Cardiac 
mortality plus heart transplantation rates at 1 and 5 years 
were 3% and 4.1%. Cardiac mortality plus heart 
transplantation rates were 11.3% and 14.7% in patients 
with complicated presentation and 0% in uncomplicated 
cases (log-rank P<0.0001). Major AM-related cardiac 
events after the acute phase occurred in 2.8% at the 5-year 
follow-up, with a higher incidence in patients with 
complicated forms (10.8% vs 0% in uncomplicated AM; 
log-rank P<0.0001). β-blockers were the most frequently 
used medications. After a median time of 196 days, 200 
patients had follow-up CMR, and 8 of 55 (14.5%) with 
complications at presentation had LVEF <50% compared 
with 1 of 145 (0.7%) of those with uncomplicated 
presentation (Ammirati E et al, Circulation 2018;138: 
1088–99).   
Only the SCN5A Gene was Classified as Having 
Definitive Evidence as a Cause for Brugada Syndrome 
(BrS) 
Of 21 genes curated for clinical validity, biocurators 
classified only 1 gene (SCN5A) as definitive evidence of 
its association with BrS, whereas all other genes were 
classified as limited evidence. After comprehensive review 
by a clinical Expert panel, all 20 genes classified as limited 
evidence were reclassified as disputed with regard to any 
assertions of disease causality for BrS (Hosseini SM et al, 
Circulation 2018;138:1195–1205).   
FAME-2: Favorable 5-Year Outcomes of PCI Guided 
by Fractional Flow Reserve (FFR) 
Among 888 patients (FFR-guided PCI) undergoing 
randomization (447 patients in the PCI group and 441 in 
the medical-therapy group), at 5 years, the rate of the 
primary end point (death, MI, urgent revascularization) 
was lower in the PCI group than in the medical-therapy 
group (13.9% vs 27%; hazard ratio - HR, 0.46; P<0.001). 
The difference was driven by urgent revascularizations, 
which occurred in 6.3% of the patients in the PCI group vs 
21.1% in the medical group (HR, 0.27). There were no 
significant differences between the PCI group and the 
medical-therapy group in the rates of death (5.1% and 
5.2%, respectively; HR, 0.98) or MI (8.1% and 12.0%; HR, 
0.66). There was no significant difference in the rate of the 
primary end point between the PCI group and the registry 
cohort (13.9% and 15.7%, respectively; HR, 0.88). Relief 
from angina was more pronounced after PCI than after 
medical therapy (Xaplanteris P et al, N Engl J Med 2018; 
379:250-259.   
PAREMEDIC 2 Trial: In Out-Of-Hospital Cardiac 
Arrest, Epinephrine Conferred Higher Rate of 30-Day 
Survival vs Placebo, But with no Difference in 
Neurologic Outcome  
Concern about the use of epinephrine as a treatment 
for out-of-hospital cardiac arrest led to a randomized trial 
involving 8014 patients with out-of-hospital cardiac arrest 
in the UK, where paramedics administered either 
parenteral epinephrine (4015 patients) or saline placebo 
(3999 patients), along with standard care. At 30 days, 130 
patients (3.2%) in the epinephrine group and 94 (2.4%) in 
the placebo group were alive (odds ratio – OR for survival, 
1.39; P=0.02). There was no evidence of a significant 
difference in the proportion of patients who survived until 
hospital discharge with a favorable neurologic outcome 
(2.2% vs 1.9%; OR, 1.18). At the time of hospital 
discharge, severe neurologic impairment (a score of 4 or 5 
on the modified Rankin scale) had occurred in more of the 
survivors in the epinephrine group than in the placebo 
group (31% vs 17.8%) (Perkins GD et al, N Engl J Med 
2018; 379:711-721).   
ATTR-ACT: Tafamidis is an Effective Therapy for 
Transthyretin Amyloid Cardiomyopathy 
Tafamidis, a benzoxazole derivative lacking non-
steroidal anti-inflammatory drug activity that binds to the 
thyroxine-binding sites of transthyretin and inhibits the 
dissociation of tetramers into monomers, was tested in 441 
patients with transthyretin amyloid cardiomyopathy. All-
cause mortality and rates of cardiovascular-related 
hospitalizations were lower among the 264 patients who 
received tafamidis than among the 177 patients who 
received placebo (P<0.001). Tafamidis was associated 
with lower all-cause mortality (29.5% vs 42.9%; hazard 
ratio, 0.70) and a lower rate of cardiovascular-related 
hospitalizations, with a relative risk ratio of 0.68 (0.48 vs 
0.70 per year). At month 30, tafamidis was also associated 
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with a lower rate of decline in distance for the 6-minute 
walk test (P<0.001) and better quality of life (P<0.001). 
The incidence and types of adverse events were similar in 
the two groups (Maurer MS et al, N Engl J Med 2018; 
379:1007-16).   
CAMELLIA–TIMI 61: In High-Risk Overweight or 
Obese Patients, Lorcaserin Facilitated Sustained 
Weight Loss Without a Higher Rate of Major 
Cardiovascular (CV) Events   
Among 12,000 overweight or obese patients with 
atherosclerotic CV disease or multiple CV risk factors, 
randomly assigned to receive either lorcaserin (10 mg bid) 
or placebo, at 1 year, weight loss of at least 5% had 
occurred in 38.7% in the lorcaserin group and in 17.4% in 
the placebo group (odds ratio, 3.01; P<0.001). Patients in 
the lorcaserin group had slightly better values with respect 
to CV risk factors. During a median of 3.3 years, the rate 
of the primary safety outcome (CV death, MI, or stroke) 
was 2% per year in the lorcaserin group and 2.1% per year 
in the placebo group (hazard ratio-HR, 0.99; P<0.001 for 
noninferiority); the rate of extended major CV events was 
4.1% per year and 4.2% per year, respectively (HR, 0.97; 
P=0.55). Except for a higher number of patients with 
serious hypoglycemia in the lorcaserin group (13 vs. 4, 
P=0.04), other adverse events were similar (Bohula EA et 
al, N Engl J Med 2018; 379:1107-17).   
VEST: Among Patients With a Recent Myocardial 
Infarction (MI) and an Ejection Fraction (LVEF) 
<35%, the Wearable Cardioverter–Defibrillator 
(WCD) did not Lower Arrhythmic Death  
Among 2302 MI patients with LVEF <35%, 1524 
randomly assigned to the device (WCD) group (wearing it 
for a median of 18 h/d) and 778 to the control group, 
arrhythmic death occurred in 1.6% in the device group and 
in 2.4% in the control group (relative risk, 0.67; P=0.18). 
Death from any cause occurred in 3.1% vs 4.9% 
respectively (relative risk-RR, 0.64; P=0.04), and non-
arrhythmic death in 1.4% and 2.2%, respectively (RR, 
0.63; P=0.15). Of the 48 participants in the device group 
who died, 12 were wearing the device at the time of death. 
Twenty patients in the device group (1.3%) received an 
appropriate shock and 9 (0.6%) received an inappropriate 
shock (Olgin JE et al, N Engl J Med 2018; 379:1205-15).   
Electric Cars did not Affect CIED Function or 
Programming / However, Vigilance is Recommended 
to Monitor for Rare Events, Especially Those 
Associated With Charging and Proposed 
“Supercharging” Technology  
Among 108 patients fitted with cardiac implantable 
electronic devices (CIEDs; 34 pacemakers, 74 ICDs) for 
several indications who were tested for electromagnetic 
interference (EMI) by electric cars, no evidence of EMI 
with CIEDs was found. There were no episodes of over- or 
under-sensing, inappropriate pacing or pacing inhibition, 
or device reprogramming (incidence of EMI, 0%). 
Postexposure testing also revealed that pacing thresholds, 
sensing, and lead impedance remained unchanged. The 
electrocardiographic recorder did observe EMI, but CIED 
function and programming were unaffected (Lennerz C et 
al, Ann Intern Med 2018;169: 350-52).  
Tailored (Weight-Adjusted) Strategy for Aspirin in 
Primary Prevention: Low Doses (75–100 mg) are Only 
Effective in Preventing Cardiovascular (CV) Events in 
Patients Weighing <70 kg / Higher Doses are Only 
Effective in Patients Weighing >70 kg  
Among 10 eligible trials of aspirin in primary 
prevention (117,279 participants), the ability of 75–100 
mg aspirin to reduce CV events decreased with increasing 
weight (pinteraction=0ꞏ0072), with benefit seen in people 
weighing 50–69 kg (hazard ratio - HR 0.75) but not in 
those weighing >70 kg (HR 0.95; 1.09 for CV death). The 
case fatality of a first CV event was increased by low-dose 
aspirin in people weighing >70 kg (odds ratio 1.33, 
p=0ꞏ0082). Higher doses of aspirin (≥325 mg) had the 
opposite interaction with bodyweight, reducing CV events 
only at higher weight (pinteraction=0.017). Findings were 
similar in men and women, in people with diabetes, in 
trials of aspirin in secondary prevention, and in relation to 
height (pinteraction=0.0025 for CV events). Aspirin-mediated 
reductions in long-term risk of colorectal cancer were also 
weight dependent (pinteraction=0.038). Stratification by body 
size also revealed harms due to excess dosing: risk of 
sudden death was increased by aspirin in people at low 
weight for dose (pinteraction=0.0018) and risk of all-cause 
death was increased in people weighing less than 50 kg 
who were receiving 75–100 mg aspirin (HR 1.52, 
p=0ꞏ031). In participants aged >70 years, the 3-year risk of 
cancer was also increased by aspirin (HR 1.20, p=0.02), 
particularly in those weighing <70 kg (1.31, p=0.009) and 
consequently in women (HR 1.44, p=0.0069) (Rothwell 
PM JL et al, Lancet 2018;392:387-99).  
PURE: Sodium Intake was Associated With 
Cardiovascular (CV) Disease (CVD) and Strokes Only 
in Communities Where Mean Intake was >5 g/d  
WHO recommends consuming <2 g/day sodium as a 
preventive measure against CVD, but this target has not 
been achieved in any country. Among 95,767 participants 
in 369 communities/18 countries assessed for BP and 
82,544 in 255 communities for CV outcomes over a 
median of 8.1 years, overall, mean systolic BP increased 
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by 2.86 mmHg per 1 g increase in mean sodium intake, but 
positive associations were only seen among the 
communities in the highest tertile of sodium intake 
(p<0.0001). The association between mean sodium intake 
and major CV events showed significant deviations from 
linearity (p=0.043) due to a significant inverse association 
in the lowest tertile of sodium intake (lowest tertile <4.43 
g/d, p=0.0497), no association in the middle tertile (middle 
tertile 4.43–5.08 g/day, p=0.8391), and a positive but non-
significant association in the highest tertile (highest tertile 
>5.08 g/d, p=0.0712). A strong association was seen with 
stroke in China (mean sodium intake 5.58 g/day, 0.42 
events per 1000 years, p=0.0020) compared with in other 
countries (4.49 g/day, –0.26 events, p=0.0124; p<0.0001 
for heterogeneity). All major CV outcomes decreased with 
increasing potassium intake in all countries (Mente A et al, 
Lancet 2018;392:496-506).   
MATRIX: In Patients With Acute Coronary 
Syndrome, Radial Access was Associated With Lower 
Rates of Net Adverse Clinical Events Compared With 
Femoral Access, but not Major Adverse Cardio-
vascular Events (MACE) at 1 Year. Bivalirudin did not 
Confer Any Benefit Over Heparin 
Among 8404 patients randomly assigned to radial 
(4197 patients) or femoral (4207 patients) access, and 7213 
randomly assigned to bivalirudin (3610 patients) or 
heparin (3603 patients), at 1 year, MACE did not differ 
(14.2% vs 15.7%; rate ratio-RR 0.89; p=0.0526), but net 
adverse clinical events were fewer with radial than with 
femoral access (15.2% vs 17.2%; RR 0ꞏ87; p=0.0128). 
Compared with heparin, bivalirudin was not associated 
with fewer MACE (15.8% vs 16.8%; RR 0.94; p=0.28) or 
net adverse clinical events (17% vs 18.4%; RR 0.91; 
p=0.10) (Valgimigli M et al, Lancet 2018; 392:835-48).   
BASKET-SMALL 2: In Small Native Coronary Artery 
Disease, Drug-Coated Balloons (DCB) was Non-
Inferior to DES Regarding MACE up to 1 Year, With 
Similar Event Rates for Both Treatment Groups 
Among 382 patients randomly assigned to the DCB 
group and 376 to DES group, non-inferiority of DCB vs 
DES was shown. After 1 year, the proportions of MACE 
were similar in both groups (MACE was 7.5% for the DCB 
vs 7.3% for the DES group; hazard ratio -HR 0.97, 
p=0.9180). There were 5 (1.3%) cardiac-related deaths in 
the DES group and 12 (3.1%) in the DCB group. Probable 
or definite stent thrombosis (0.8% in the DCB vs 1.1% in 
the DES group; HR 0.73) and major bleeding (1.1% in the 
DCB vs 2.4% in the DES group; HR 0.45) were the most 
common adverse events (Jeger RV, Lancet 2018;392:849-
56).  
ASCOT Legacy Study: Long-Term Beneficial Effects 
on Mortality of Antihypertensive and Hypolipidemic 
Treatment / Patients on Amlodipine-Based Treatment 
Had Fewer Stroke Deaths and Patients on Atorvastatin 
Had Fewer Cardiovascular (CV) Deaths >10 Years 
After Trial Closure   
Over 16 years, among 8580 UK-based patients in 
ASCOT, in the BP lowering arm (BPLA), there were 
significantly fewer deaths from stroke (adjusted HR 0.71, 
p=0.0305) in the amlodipine-based treatment group than in 
the atenolol-based treatment group. In the 3975 patients in 
the non-lipid-lowering arm (LLA) group, there were fewer 
CV deaths (adjusted HR 0.79, p=0.0046) among those 
assigned to amlodipine-based treatment (p=0.022). In the 
LLA, significantly fewer CV deaths (HR 0.85, p=0.0395) 
occurred among patients assigned to statin than among 
those assigned placebo (Gupta A et al, Lancet 
2018;392:1127-37).   
Higher Dose of β-Blocker Therapy (>25 mg/d for 
Carvedilol or >100 mg/d For Metoprolol) and a Lower 
Achieved Heart Rate (HR) (Mean 64-77 bpm) Were 
Independently Associated With a Reduction in 
Mortality in HFrEf Patients  
A total of 36,168 patients on low-dose β-blocker 
(carvedilol <25 mg/d or metoprolol <100 mg/d) were 
matched with 36,168 patients on high dose β-blocker using 
propensity score matching. High β-blocker dose was 
associated with lower overall mortality as compared with 
a low dose of β blocker (hazard ratio 0.75, p <0.01) 
independent of the HR achieved. The results held for all 4 
quartiles of average HR. A higher β-blocker dose or a 
lower HR were independently and jointly associated with 
lower mortality for all quartiles of HR (Ajam T et al, Am J 
Cardiol 2018;122:994-8).  
Meta-Analysis: Catheter Ablation of Atrial Fibrillation 
(AF) in Patients with Heart Failure (HF) is Associated 
With Improved Survival and HF Hospitalizations 
Compared With Medical Therapy  
Among 775 ambulatory AF patients from 6 trials with 
HF and a mean LVEF of 31% (mean NYHA class 2.5), 
over 26 months, ablation was associated with lower 
incidences of all-cause mortality (RR 0.50, p <0.0001), and 
HF hospitalizations (RR 0.58, p = 0.002), with similar 
incidences of stroke. Improvement in LVEF and quality of 
life were also noted, with no change in 6-minute walk test. 
The incidence of all reported procedural complications 
(including major and minor) was 7.3% (Elgendy LY et al, 
Am J Cardiol 2018;122:806-13).   
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TAVI for Aortic Regurgitation (AR): Feasible in 
Selected High-Risk Patients Albeit With Considerable 
Risk of Valve Malpositioning and Residual AR  
Among 254 AR patients (age 74 ± 12 years, STS score 
6.6±6.2%) undergoing TAVI, success was higher with 
newer (82%) vs early generation (47%) devices (p <0.001), 
driven by lower rates of device malpositioning (9% vs 
33%) and AR ≥ moderate (4% vs 31%), translating into 
higher clinical efficacy at 30 days in patients treated with 
newer devices (72% vs 56%, p = 0.041). Both device 
under- and oversizing were associated with an increased 
risk of malpositioning (De Baker O et al, Am J Cardiol 
2018;122:1028-35).   
DETO2X-AMI Trial: No Benefit of Routine Use of 
Supplemental Oxygen in Normoxemic Patients With 
STEMI Undergoing Primary PCI   
Among 2807 patients with STEMI undergoing PCI 
randomized to receive oxygen at 6 L/min for 6–12 h or 
ambient air, the pre-specified primary composite endpoint 
of all-cause death, rehospitalization with MI, cardiogenic 
shock, or stent thrombosis at 1 year occurred in 6.3% vs 
7.5% (hazard ratio - HR 0.85; P = 0.27). There was no 
difference in the rate of death from any cause (HR 0.86; 
P = 0.41), rate of rehospitalization for MI (HR 0.92; 
P = 0.73), rehospitalization for cardiogenic shock (HR 
1.05; P = 0.95), or stent thrombosis (HR 1.27; P = 0.64) 
(Hoffman R et al, Eur Heart J 2018;39:2730-39).   
Continuing Apixaban Peri-Procedurally was “Safe” in 
Patients Undergoing Atrial Fibrillation (AF) Ablation / 
But ¼ Had Ablation-Related Acute Brain Lesions   
Overall, 674 AF patients (median age 64 years, 33% 
female, 42% non-paroxysmal AF) undergoing ablation 
were randomized; 633 received study drug (apixaban at 
5 mg bid or vitamin K antagonists - VKA, INR 2–3); 335 
had MRI. The primary outcome (death, stroke, or 
bleeding) was observed in 22/318 patients randomized to 
apixaban, and in 23/315 randomized to VKA (difference 
−0.38%, non-inferiority P = 0.0002), including 2 (0.3%) 
deaths, 2 (0.3%) strokes, and 24 (3.8%) major bleeds. 
Acute small brain lesions were found in a similar number 
of patients in each arm (apixaban 27.2%, VKA 24.8%; 
P = 0.64). Cognitive function increased at the end of 
follow-up without differences between study groups 
(Kirchhof P et al, Eur Heart J 2018;39:2942-55). 
 
 
 
 
 
 
Important Review and Other Articles   
● 2018 ESC/ESH Hypertension Guidelines (Williams B et al, 
Eur Heart J 2018;39:3021-3104) 
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● Cardiorenal syndrome (Zannad F & Rossignol P, Circulation 
2018;138:929-44) 
● Ventricular arrhythmias in cardiac sarcoidosis (Okada DR et 
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● Hypertrophic cardiomyopathy (Maron BJ, New Engl J Med 
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● Adverse effects of statin therapy (Mach F et al, Eur Heart J 
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● TAVI (Cahill TJ et al, Eur Heart J 2018; 39:2625–34) 
● 2018 ESC Guidelines for management of CV diseases during 
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3241) 
● Management of antithrombotic therapy in AF patients 
presenting with ACS and/or undergoing PCI (Lip GYH et al, Eur 
Heart J 2018;39:2847-50) 
● ESC Position paper on spontaneous coronary dissection 
(Adlam D et al, Eur Heart J 2018;39:3353-68)  
● New-onset arrhythmias following TAVI (Siontis GCM et al, 
Heart 2018;104:1208-15) 
● Optimal CRT (Chousou PA & Pugh PJ, Heart 2018;104:1300-
07)  
● Cardiovascular safety of oncologic agents (Manolis AA et al, 
Exp Opin Drug Saf 2018;17: 875-92 & 893-915) 
● Perioperative management of anticoagulant and anti-platelet 
therapy (Tafur A & Duketis J, Heart 2018;104: 1461-67) 
